Myriad Genetics (NASDAQ:MYGN) Releases Q4 Earnings Guidance

Myriad Genetics (NASDAQ:MYGN) updated its fourth quarter earnings guidance on Wednesday. The company provided earnings per share (EPS) guidance of $0.03-0.04 for the period, compared to the consensus estimate of $0.03. The company issued revenue guidance of $209-211 million, compared to the consensus revenue estimate of $212.87 million. Myriad Genetics also updated its FY25 guidance to $0.07-0.11 EPS.

Myriad Genetics Stock Performance

Shares of Myriad Genetics stock opened at $13.68 on Wednesday. The company has a 50 day moving average price of $15.05 and a 200 day moving average price of $22.17. The firm has a market capitalization of $1.25 billion, a P/E ratio of -10.52 and a beta of 1.89. The company has a quick ratio of 1.73, a current ratio of 1.90 and a debt-to-equity ratio of 0.05. Myriad Genetics has a 52 week low of $12.87 and a 52 week high of $29.30.

Wall Street Analyst Weigh In

MYGN has been the subject of several research reports. UBS Group started coverage on shares of Myriad Genetics in a research note on Tuesday, December 10th. They set a “neutral” rating and a $18.00 price objective for the company. Leerink Partnrs cut Myriad Genetics from a “strong-buy” rating to a “hold” rating in a research report on Monday, December 9th. StockNews.com raised Myriad Genetics from a “hold” rating to a “buy” rating in a report on Thursday, January 9th. Bank of America decreased their target price on Myriad Genetics from $15.00 to $13.00 and set an “underperform” rating for the company in a report on Friday, December 13th. Finally, Morgan Stanley cut their price target on shares of Myriad Genetics from $32.00 to $21.00 and set an “equal weight” rating on the stock in a report on Monday, November 18th. Three research analysts have rated the stock with a sell rating, six have issued a hold rating and four have issued a buy rating to the stock. According to MarketBeat, the stock currently has an average rating of “Hold” and a consensus price target of $24.27.

Myriad Genetics Company Profile

Myriad Genetics, Inc, a genetic testing and precision medicine company, develops genetic tests in the United States and internationally. The company offers molecular diagnostic tests for use in oncology, and women's and pharmacogenomics. It also provides MyRisk Hereditary Cancer Test, a DNA sequencing test for assessing the risks for hereditary cancers; BRACAnalysis CDx Germline Companion Diagnostic Test, a DNA sequencing test to help determine the therapy for patients with metastatic breast, ovarian, metastatic pancreatic, and metastatic prostate cancer with deleterious or suspected deleterious germline BRCA variants; and MyChoice CDx Companion Diagnostic Test, a tumor test that determines homologous recombination deficiency status in patients with ovarian cancer.